Intercept Pharmaceuticals: Developing the Cure for Liver Diseases

One of the pharmaceutical companies that have taken on the challenge of providing novel therapeutics to some unmet areas of medicine is Intercept Pharmaceuticals. This biotechnology business got started in 2002 and focuses its research and development in the creation of synthetic bile acid analogs to treat various chronic liver diseases.

The main product of the business is referred to as the Obeticholic acid (OCA). This product is also referred to as the INT-747 or the 6-ethyl-chenodeoxycholic acid and is listed as a farnesoid X receptor (FXR) agonist. This product offering is intended to create a combatant that would treat various common diseases that have limited to almost non-existent therapeutic solutions. These illnesses include non-alcoholic fatty liver diseases, cirrhosis, primary biliary cirrhosis (PBC), bile acid diarrhea, portal hypertension and primary sclerosing cholangitis. This product hasn’t reached the market yet and is still on its phase III studies for primary biliary cirrhosis. There are also other products that the business is in the process of developing for intestinal and chronic liver diseases.

Through the research and development efforts of Intercept Pharmaceuticals, people who are suffering liver diseases are given hope that they can soon live a normal and quality life. The innovative and breakthrough therapeutics that the company is developing intends to reverse the damage done to the liver of these patients. The FXR agonist that they are developing can also be a potential cure for several other diseases that impacts the intestine and kidneys.

Intercept Pharmaceuticals works closely with other research organizations, including the University of Perugia. With their strong ties with experts in the subject matter, the business has maintained their leading position in the research and development of therapeutics for bile acid chemistry.

The business is a publicly held company with common stocks traded on the NASDAQ. It holds its main office in New York City.